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Abstract: The targeting of protein–protein interactions (PPIs) that include secondary structure 
motifs such as the α-helix and β-sheet is a challenge in chemical biology. A new class of com-
pounds called stapled peptides have been developed that mimic α-helix secondary structures 
involved in PPIs. These conformationally constrained peptides also show favorable physicochemi-
cal properties and so are promising lead compounds for drug discovery. This review focuses on 
the design aspects of hydrocarbon constrained α-helical proteomimetics and provides examples 
in which they target biologically relevant PPIs.
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Introduction
Protein–protein interactions (PPIs) are becoming increasingly popular drug targets 
because the chemical space required for inhibition is underexplored and so the intel-
lectual property landscape is relatively barren.
However, the development of novel, cell-permeable molecules that regulate PPIs 
remains one of the major challenges in chemical biology due to the relatively large 
(typically ∼1600 Å2) and dynamic nature of the PPI interface. While these molecular 
recognition events involve interactions over large surface areas, the majority of the 
binding affinity and specificity has been found to originate from constellations of a 
few amino acid residues that are described as interaction “hotspots”.1 At a molecular 
level, these constellations of residues are frequently found to be specific protein sec-
ondary structures such as the α-helix or -strand. Although these motifs are usually 
thermodynamically favored in folded proteins, isolated peptides typically lack the 
ability to spontaneously adopt these bioactive conformations. Peptides also have a 
number of other therapeutically undesirable properties including poor bioavailability, 
limited stability toward peptidase proteolysis, and lack of membrane permeability that 
can potentially limit their use as drugs.
A challenge therefore exists to design molecules that occupy the chemical space 
large enough to modulate PPIs and yet small enough to have suitable drug-like 
physicochemical properties. Recent research efforts have focused on the design and 
synthesis of proteomimetics, molecules that mimic both the structure and/or function 
of proteins. Many different strategies have been used to interrogate PPIs and these 
have previously been reviewed.2,3 Proteomimetics, and stapled peptides in particular, 
are proving useful for targeting PPIs.4,5 The main focus of this review is the design, 
synthesis, and application of stapled peptides as molecular probes to disrupt PPIs.
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Figure 1 Structures of small molecule peptidomimetic inhibitors (A) ABT-737, (B) ABT-263 that target the Bcl-xL/Bak PPii, (C) Nutlin-2, and (D) benzodiazepinedione-1 
that target the p53/mDM2 PPi.
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Strategies for targeting PPIs
Many different strategies for targeting PPIs have been stud-
ied, including the use of small molecule peptidomimetic 
inhibitors, which include ABT-7376 and ABT-2637 from 
Abbott Laboratories, that were found to be inhibitors of the 
Bcl-x
L
/Bak PPI (Figure 1). Additionally, the Nutlin8 and 
benzodiazepinedione9 families of compounds, developed by 
Hoffman-La Roche and Johnson & Johnson pharmaceuticals, 
respectively, were found to be inhibitors of the p53/mDM2 
PPI. As well as small molecules, nonpeptidic scaffolds can 
be used to target PPIs such as the terphenyl scaffolds first 
developed by the Hamilton group.10 Hara et al have devel-
oped polyproline-type helix peptoids that target the p53/
mDM2 PPI.11
A large proportion of the PPIs that have been reported are 
mediated by α-helices.12 Particular emphasis has therefore 
been placed on the design of conformational constraints that 
induce α-helix structure. Examples of α-helix constraints 
include salt bridges between charged amino acid side chain 
residues,13,14 lactam bridges,15,16 disulfide bridges,17 hydro-
gen bond surrogates,18,19 hydrophobic interactions,20 metal 
ligation,21,22 triazole staples synthesized from alkenyl and 
azido side chain residues,23 photocontrollable macrocycles,24 
introduction of α,α-disubstituted amino acids,25,26 and hydro-
carbon staples27 (Figure 2). In addition, short α-helical pep-
tides have been nucleated with the help of capping groups28–30 
and using designed molecules to template the helix.31,32
Proteomimetic compounds of this type demonstrate a 
number of attractive physicochemical properties in com-
parison with small molecules, peptides, and biologics. For 
example, improved binding affinity is observed by overcom-
ing the entropic penalty associated with peptide folding. 
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Figure 2 Strategies to constrain α-helical peptides.
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Good target specificity relative to small molecules and 
comparable to biologics is achieved due to maintaining 
the original amino acid residues, with the correct orienta-
tion and spacing, to facilitate the molecular recognition 
event. Conformational constraints also prevent the required 
extended sheet conformation for recognition by peptidases 
and so proteomimetics generally have a significantly longer 
half-life in blood serum.
Of these techniques, hydrocarbon stapling is coming of 
age as a method to develop peptidomimetic drugs that regu-
late PPIs and so will be the main focus of this article.
Hydrocarbon peptide stapling
The first “stapled” peptide was reported by Miller et al33,34 
and Blackwell et al35 in 1998. The effects of using ring clos-
ing metathesis (RCM) on peptide antibiotics containing 
two alkenyl side chains and rich in α-aminoisobutyric acid 
(Aib) residues are known to constrain 3
10
-helices through the 
Thorpe–Ingold effect.25,36,37
More recently, Korsmeyer, Verdine, and Walensky have 
developed the rules for effective peptide stapling,27,38 thus 
making the technology transferable to other PPIs. The social 
and economic value of this approach became apparent in 
2005 with the foundation of Aileron Therapeutics, Inc. to 
develop and commercialize a drug-discovery pipeline based 
on stapled peptides.39 In 2013, the company announced the 
successful completion of the first-in-human clinical trial 
of a stapled peptide drug, ALRN-5281 for the treatment 
of rare endocrine diseases such as adult growth hormone 
deficiency and HIV lipodystrophy. The main outcome of the 
trial showed ALRN-5281 had no incidence of adverse events 
in healthy subjects.40 Additionally, Aileron Therapeutics is 
also developing a new stapled peptide drug, ATSP-7041, 
that targets intracellular PPIs. The i, i+7 hydrocarbon staple 
feature of ATSP-7041 increases its helicity from 11% in its 
linear form to 70% helical in the stapled form at pH 7.0.41 
The study showed that ATSP-7041 is a potent dual inhibitor 
of MDM2 and MDMX, which are proteins overexpressed 
in cancers and deactivate p53 function. Thus, ATSP-7041 
can reactivate the p53 pathway, including the inducement of 
cell-cycle arrest and apoptosis.41
Since the early works of Korsmeyer, Verdine, and 
Walensky, many other PPIs have been studied using stapled 
peptides. These include cancer targets such as p53,42 MCL-1 
BH3,43 and PUMA BH344 and other therapeutic targets rang-
ing from infectious diseases45,46 to metabolism.47,48 Obtaining 
crystal structures of stapled peptides bound to their targets is 
not trivial. In fact, there are less than 15 stapled peptide crys-
tal structures available in the literature including an estrogen 
receptor beta binding stapled peptide48 and a MCL-1 BH3 
stapled peptide43 (Figure 3). Interestingly, in these solid-state 
structures, the hydrocarbon staple functionality appears to 
form hydrophobic interactions with the surface of the target 
proteins and has been proposed to provide additional binding 
affinity.43,47 Recent work by the Tate group has also revealed 
the crystal structures of stapled and hydrogen bond surro-
gate α-helical peptides in a fully buried binding site.49 The 
fully buried stapled peptides present polar and hydrophobic 
functionalities on all sides of the peptide helix. These results, 
along with crystallographic data from Chang et al where 
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Figure 3 Crystal structures of (A) a BH3 stapled peptide (blue) bound to MCL-1 (gray) (PDB: 3MK8) and (B) a nuclear receptor helix stapled peptide (red) bound to 
estrogen receptor beta (gray) (PDB: 2YJD).
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stapled peptide ATSP-7041 was bound to MDMX,41 suggest 
the hydrophobic hydrocarbon staple can help in target binding 
and not just act as a nonparticipating constraint.
Stapled peptides have been used extensively to develop 
potential anticancer drugs through the regulation of PPIs 
involving the BCL-2 family of proteins implicated in cell 
apoptosis. Stapled peptide mimics of BH3 domain segments 
showed α-helical conformation when compared to the native 
sequences.38 It was also found that stapling of the BH3 pep-
tides gave protease resistance both in vitro and in vivo in 
comparison to the unmodified peptides.38 This phenomenon 
is accounted for by the fact that proteases require peptides to 
be in an extended conformation in order to access the peptide 
backbone and hydrolyze the amide bond. However, by incor-
poration of a staple, the peptide is forced into the α-helical 
conformation and so the amide backbone is inaccessible.
Ring closing metathesis
Hydrocarbon stapling involves joining two alkenyl side 
chains to form a macrocycle using ruthenium-catalyzed 
RCM as the key step in the synthesis. On-resin peptide RCM 
was first carried out by Miller et al in 1996.34 Due to their 
good functional group tolerance, ruthenium-based catalysts 
required for RCM are particularly well-suited for use on 
peptide substrates.
Miller et al’s initial work involved the synthesis of cyclic 
peptides through incorporation of allyl groups onto the side 
chain of serine residues, followed by RCM to create peptides 
of varying ring sizes.34 Following this, the efficient cross-
linking of an Aib-containing heptapeptide was achieved by 
replacing two alanine residues at i and i+4 positions with 
unbranched O-allyl serine or homoserine residues. The two 
terminal alkene moieties on the peptide were then treated 
with Grubbs’ first generation catalyst to afford the macro-
cyclic peptide in high yield.35 Catalytic hydrogenation then 
provided peptides with a 3
10
-helix structure as determined by 
circular dichroism (CD) spectroscopy. The ease of RCM on 
these peptides has been attributed to the preorganization of a 
3
10
-helix on solid support facilitated by the Aib residues.
Structural requirements for stapling
The combined use of α,α-disubstituted alkenyl amino acid 
residues and RCM to produce all-hydrocarbon stapled pep-
tides was first conceived by Schafmeister et al in 2000.27 
Initial work investigated the structural requirements needed 
for effective peptide stapling, including the length of the 
hydrocarbon bridge and the α-carbon stereochemistry of the 
α,α-disubstituted unnatural alkenyl amino acids (Figure 4).
A strategically useful feature of peptide stapling is that 
the hydrocarbon constraint can be incorporated at different 
positions along the peptide sequence. The most common 
types of peptide staple form a side chain–side chain bridge 
between the i, i+3, i, i+4 or i, i+7 residues. With shorter 
peptides a constraint across one turn of the helix (ie, i, i+3 or 
an i, i+4 staple) is employed. The i, i+3 type staple requires 
one R- and one S-pentenyl alanine (Figure 4A), whereas 
two S-pentenyl alanine residues are required for an i, i+4 
type staple (Figure 4B). An i, i+7 staple provides a hydro-
carbon bridge spanning two turns of the helix and requires 
a S-pentenyl alanine and an R-octenyl alanine (Figure 4C). 
Again, the stereochemistry of these amino acids is very 
important to develop an effective constraint.
 
R
ep
or
ts
 in
 O
rg
an
ic 
Ch
em
ist
ry
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
9.
11
5.
82
 o
n 
31
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Reports in Organic Chemistry 2015:5
A B C
D
Si, i+3R(8)
Double staple Stitched staple
Si, i+4S(8) Ri, i+7S(11)
E
Figure 4 Representation of three types of stapled peptide constraints: (A) i, i+3; (B) i, i+4; (C) i, i+7; indicating the stereochemistry required for the stapled amino acids and 
the multiple stapling techniques used to constrain longer helices; (D) double staple; and (E) stitched staple.
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Staple scanning
When limited structural information is available regarding 
a specific PPI, a staple scan can be used to determine the 
most effective position for the hydrocarbon constraint. This 
involves positioning an appropriate staple sequentially along 
the length of the peptide sequence. Staple scanning echoes 
the alanine scanning technique by also helping to determine 
if a residue is required for binding affinity.50
This strategy has been used to identify a selective inhibi-
tor of MCL-1, a human cancer resistance factor.43 Stewart 
et al found that the peptide, which had the highest α-helical 
character, as shown by CD, also had the highest binding 
affinity for MCL-1.43
An extension of the peptide stapling approach for lon-
ger helical peptide sequences involves the incorporation of 
multiple hydrocarbon bridges. These can take the form of 
multiple individual staples (Figure 4D) or “stitched” stapled 
peptides incorporating two alkenyl chains on one α-carbon 
of the central amino acid (Figure 4E).51–54 One staple con-
straint has been shown to be ineffective for longer peptides; 
however, two staple constraints can significantly increase the 
helicity.54 Stitched α-helical peptides can be thought to be 
the next generation in terms of hydrocarbon stapling, creat-
ing spiro-macrocycles, which are known to be stabilizing. 
Stitched peptides have been shown to give increased helicity, 
protease resistance, and cell permeability compared to the 
monostapled peptides.54
The size of the macrocycle formed upon RCM is important 
to achieve an increased degree of helicity in the constrained 
α-helical peptide. Different ring sizes are achieved depend-
ing on the length of the amino acid side chains used for 
the RCM. The macrocycle formed upon RCM of an i−i+4 
stapled peptide consists of 21 atoms, eight of which form 
the hydrocarbon constraint. This macrocycle is large in size 
and would generally mean that it would be problematic to 
ring close. However, the RCM reaction on these peptide sub-
strates is relatively straightforward. This is due, in part, to the 
α-methyl-substituent of the alkenyl amino acid inducing the 
Thorpe–Ingold effect55,56 on the peptide backbone, as well as 
the presence of a hydrophobic environment as a result of using 
nonpolar solvents, which promotes helix formation.57
Peptides incorporating the α,α-disubstituted amino acid 
Aib were first described by Karle and Balaram and were 
shown to adopt 3
10
-helix structures.25 The α-carbon dim-
ethyl substitution of Aib restricts the torsion angles of the 
peptide bonds to ϕ=-49° and ψ=-26° in comparison to that 
of α-helix torsion angles, ϕ=-57° and ψ =-47°.58 As a result 
of these bond angles, the hydrogen bonding network of the 
two types of helices differ (Figure 5). The α,α-disubstituted 
alkenyl amino acids required for peptide stapling also appear 
to provide this effect, resulting in the peptide substrates being 
folded ready to undergo RCM.
Monosubstituted hydrocarbon staples have been success-
fully synthesized using RCM on some peptide sequences.43,59 
 
R
ep
or
ts
 in
 O
rg
an
ic 
Ch
em
ist
ry
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
9.
11
5.
82
 o
n 
31
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Reports in Organic Chemistry 2015:5
Figure 5 Representations of the (A) top view, (B) side view of an α-helix, (C) top 
view, and (D) side view of a 310-helix, showing the hydrogen bonding pattern (pink 
dotted lines) of the two types of helices.
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Figure 6 Asymmetric synthesis of Fmoc-S5-OH via fluorine-modified nickel (II) Schiff base complex.
Abbreviations: Fmoc, fluorenylmethyloxycarbonyl; OSu, O-succinimide; DMF, N,N-Dimethylformamide.
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However, it is preferable to incorporate an α,α-disubstituted 
amino acid, or some other helicity inducing substituent into 
the peptide to help promote the helical conformation and 
facilitate the RCM reaction. Although introduction of a 
hydrocarbon staple can improve the therapeutic properties of 
certain peptides,38,43,52,60 it has been found that the increased 
degree of helicity obtained through the incorporation of 
a hydrocarbon staple does not necessarily correlate to an 
increase in its binding affinity.61 This is partly because of 
the need for some flexibility to allow induced fit binding of 
some peptides to their binding partners.
Asymmetric α,α-disubstituted 
amino acid synthesis
The α,α-disubstituted alkenyl amino acids required for pep-
tide stapling are commercially available, although they are 
expensive relative to standard fluorenylmethyloxycarbonyl 
(Fmoc) protected amino acids.
Asymmetric synthesis of the required alkenyl amino acids 
has been reported using Williams’ glycine enolate alkylation 
method and alkylation of Belokon’s nickel (II) Schiff base 
complex.62–65 The Belokon method has come to the fore as 
the most effective strategy due to the harsh conditions with 
the potential for over reduction of the alkene moiety using the 
Williams method. Aillard et al recently reported a robust and 
efficient asymmetric synthesis of unnatural alkenyl amino 
acids. A fluorine-modified NiII Schiff base complex gave 
improved diastereoselectivity of the key alkylation reaction 
(.95: 5 dr).66 This method now gives access to the required 
nonnative amino acids (Figure 6).
Design of the macrocycle constraint
Following the initial studies on peptide stapling by 
 Schafmeister et al,27 recent researches have focused on 
attempting to improve both the placement of the alkene 
in the staple and the lengths of the all-hydrocarbon staple. 
Notably, Pham et al have studied the placement of the alk-
ene within the stapled macrocycle. A comparison of alkene 
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Figure 7 Structures of (A) the three S-alkenyl amino acids: S3, S5, and S7; (B) the two R-alkenyl amino acids: R3 and R5; and the representations of the different positions 
possible for the staple in an i, i+4 staple; (C) oct-2-enyl; (D) oct-4-enyl; (E) oct-6-enyl; and in an i, i+3 staple; (F) hex-4-enyl; and (G) hex-2-enyl.
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position within the i, i+4 type stapled peptide was conducted 
using oct-2-enyl, oct-6-enyl, and the more usual oct-4-enyl 
macrocyclic constraint.57
Linear peptides incorporating a (S)-α-methyl, 
α-allylglycine (S
3
) at the i position and (S)-α-methyl, 
α-heptenylglycine (S
7
) at the i+4 position provided access 
to both the oct-2-enyl staple (S
3
–S
7
) (Figure 7C) and oct-6-
enyl staple (S
7
–S
3
) (Figure 7E). Both these peptides failed to 
undergo RCM to provide the corresponding macrocyclic pep-
tides at room temperature. In fact, RCM on the S
3
–S
7
 analog 
only proceeded at an elevated temperature of 60°C, compared 
to the original oct-4-enyl staples (S
5
–S
5
) (Figure 7D), which 
proceed at room temperature. RCM of the S
7
–S
3
 substrate 
was very poor, even at 60°C and resulted in decomposition 
of the substrate peptide at the higher temperatures. The S
3
–S
7
 
analog gave improved helicity in comparison to the native 
sequence; however, it still did not match the helicity shown 
by the S
5
–S
5
 stapled peptide.57 These results demonstrate that 
the original oct-4-enyl i, i+4 type staple contains the alkene 
functionality in the optimal position on the hydrocarbon chain 
to provide an effective constraint. The i, i+3 all-hydrocarbon 
staple has also been studied to determine the optimal length of 
hydrocarbon bridge across one turn of a helix. In general, for 
an effective i, i+3 staple an S
5
 amino acid and its enantiomer, 
an R
5
 amino acid is required. However, Shim et al have 
studied the possibility of contracting the all-hydrocarbon 
bridge by removing two methylene units.67
Unsymmetrical contraction of the bridge was studied in 
order to analyze the differing positions of the alkene within 
the staple. Most of the linear peptide substrates failed to 
undergo RCM to give the corresponding macrocyclic peptide. 
However, two of the peptides did undergo metathesis, both 
of which had an R-configuration amino acid (R
3
 or R
5
) at 
the i position and an S-configuration amino acid (S
5
 or S
3
) at 
the i+3 position (Figure 7F and G). However, the difference 
in the position of the staple within the macrocycle led to a 
pronounced difference in the α-helicity of the peptides, with 
the hex-4-enyl staple (Figure 7F) being much more helical 
(55%) than the hex-2-enyl staple (Figure 7G), which was 
15% helical.67
Shim et al have investigated the ruthenium catalysts required 
form RCM including the Grubbs first generation, Grubbs 
second generation, and Hoveyda–Grubbs catalysts. RCM was 
performed at both 25°C and 65°C using the three different 
catalysts. The results showed that Grubbs first generation cata-
lyst was the most efficient at both temperatures, but at elevated 
temperatures Grubbs second generation and Hoveyda–Grubbs 
catalysts have a significant increase in efficiency.67
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Proposed mechanism of membrane 
permeability
A notable physicochemical property of stapled peptides is 
their ability to potentially promote cell penetration as a result 
of the hydrophobic hydrocarbon staple. Evidence has recently 
been reported for stapled peptides traversing the membrane 
and entering Jurkat leukemia cells38 and human U2OS osteo-
sarcoma cells68 through a clathrin- and caveolin-independent, 
ATP-dependent pinocytotic mechanism.5,38,42,68 Accumulation 
of the stapled peptides in ATP-depleted cells was reduced 
compared to normal cells. In addition, a significant reduction 
in the uptake of the stapled peptides into cells was observed 
after treatment of the cells with sodium chlorate, which blocks 
the sulfated proteoglycans presented on the cell surface. To 
confirm this finding, the researchers also treated proteoglycan 
deficient cells with the stapled peptides and found a reduction 
in cell uptake.68 It has also been reported that cellular uptake 
can be impeded by the presence of serum for some peptides,5 
which could be as a result of competition with natural serum 
containing substrates for pinocytosis.69
Current and future directions
As with many new techniques, stapled peptides are surrounded 
by controversies, notably the recent works of two groups of 
researchers who contradict each other, and thus have initi-
ated a debate on the effectiveness of peptide stapling in drug 
discovery. In 2012, LaBelle et al reported a stapled BIM 
peptide based on the BIM BH3 helix to target the BCL-2 
family of proteins.70 The stapled peptide, BIM SAHB
A
, incor-
porated an i, i+4 all-hydrocarbon crosslink and was found 
to have increased binding in comparison to the native BIM 
BH3 helix. In addition, they found BIM SAHB
A
-induced cell 
apoptosis in leukemia by modulating the BCL-2 pathway.
Later that same year, Okamoto et al also reported a stapled 
peptide very similar to that of the previous study.71 However, 
in their hands, the stapling of the peptide did not enhance its 
affinity or biological activity. The BIM BH3 all-hydrocarbon 
stapled peptide did not in fact induce apoptosis much more 
than the native sequence and was also not inherently cell 
permeable.71 In addition, a lactam-stapled peptide based on 
the same helical sequence was found to have a greater per-
centage of helicity than the all-hydrocarbon staple.
Following this report, a rebuttal was published by Bird et al 
with the explanation that different lengths of BIM SAHB
A
 were 
synthesized for specific studies.72 A weaker binding BIM SAHB
A
 
(145–164) stapled peptide with moderate helicity compared to 
the BIM SAHB
A
 (146–166) peptide was used in the in vivo 
and nuclear magnetic resonance experiments to increase the 
peptide’s solubility and weaken its activation of BAX. BIM 
SAHB
A
 (146–166) was three residues longer, had higher helicity 
and higher binding affinity than Bim SAHB
A
 (145–164).
Okamoto et al subsequently reported data showing unsta-
pled BIM SAHB peptides (containing two pentenylalanine 
residues at i and i+4 positions, but have not been subjected 
to RCM) were as active as the stapled peptides toward two 
particular cancer cell lines.73 Thus, it was concluded that the 
stapling was not responsible for the enhanced effect on activ-
ity, but rather, by altering the sequence of the peptides, the 
innate characteristics of that peptide are also altered.
The discrepancies in these studies demonstrate the subtle-
ties in designing effectively constrained stapled peptides. 
Systematic rules for effective design are therefore urgently 
required and will be one of the main challenges for the com-
munity to address in coming years.
Recent peptide stapling techniques have returned to the 
original idea of using O-allyl homoserine residues, such 
as the stapled peptides used as inhibitors of the vitamin D 
receptor–coactivator interaction.74 In addition, the use of all- 
hydrocarbon stapling is still prevalent, with many more tar-
gets being studied. PPIs involving membrane-bound proteins 
have also been studied, such as the transmembrane (TM) heli-
ces of small multidrug resistant proteins. These TM helices 
dimerize and oligomerize, forming PPIs, to extrude relatively 
large toxic substrates through channels created in the mem-
brane, giving the resistant nature of these small multidrug 
resistant proteins.75 Stapled peptide analogs of TM4 reduced 
the degradation of the peptides in blood plasma compared to a 
linear sequence. In addition, the stapled peptide also allowed 
the disruption of the dimerization domain between two TM4 
helices, thus preventing efflux of the toxic substrates.75
Conclusion
Although still in its infancy, there is a bright future for stapled 
peptides. Current successes from stapled peptide clinical 
trials by Aileron Therapeutics are driving enthusiasm for 
the strategy in biomimetic drug development in the area of 
PPIs. In addition, stapled peptides are being used extensively 
as molecular probes in chemical biology to facilitate under-
standing of important biological mechanisms. In time, these 
examples are likely to lead to new drug discover efforts based 
on stapled peptides as lead compounds.
Future challenges include determining how stapled pep-
tides penetrate the membrane, and establishing where they 
are located after entering the cell. A systematic set of rules 
are also required that outline the most effective position to 
locate a staple within a peptide sequence. The role, if any, 
of hydrocarbon staples on binding affinity has yet to be 
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Regulation of protein–protein interactions using stapled peptides
determined, and a study focusing on nonspecific binding of 
stapled peptides is therefore required.
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